Abstract
Spontaneous regressions of human tumors have been reported in different types of cancer, especially in melanoma and renal cell carcinoma (Gromet et al. 1978; Balch et al. 1992), but also in other types of cancer such as non-small cell lung cancer, bladder carcinoma, and breast cancer. These observations suggest the interaction of the immune system with antigenic determinants presented by the tumor. Early attempts to activate the immune system against tumor growth were based on observations made in cultured melanoma cells which were shown to be lysed by autologous CD8+T lymphocytes in vitro. The clinical translation of this observation was applied to single patients with metastatic melanoma, who received irradiated autologous tumor cells as a vaccine. Two patients (SK-29 and MZ-2) with recurrent metastatic melanoma have been observed by our group since 1978 and 1982, respectively (Knuth et al. 1984). Both patients received intradermal immunization with irradiated autologous tumor cells for an extended period. Complete regression of tumor manifestations was documented after prolonged immunization with autologous tumor cells. The patients have now remained free of disease for 19 and 14 years, respectively. Based on the favorable clinical evolution in these cases, a systematic search was initiated to identify and characterize the cancer antigens and immune effector mechanisms mediating these tumor regressions in vivo (Knuth et al. 1991, 1992).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alijagic S, Müller P, Artuc M, Jurgovsky K, Czarnetzki BM, Schadendorf D (1995) Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur J Immunol 25:3100–3107
Bakker AB, Schreurs MWJ, deBoer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005–1009
Balch CM, Houghton AN, Milton GW, Soong SJ (1992) Cutaneous melanoma. Lippincott, Philadelphia
Baselga J, Mendelsohn J (1994) The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127–138
Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaye T, Degiovanni G, Deraemaecker R, Beauduin M, Sastre X, Salamon E, Dreno B, Knuth A, Jäger E, Chevreau C, Suciu S, Lachapelle J-M, Pouillart P, Parmiani G, Lejeune F, Cerottini J-C, Boon T, Marchand M (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375–380
Caux C, Dezutter-Dambuyant C, Schmitt D (1992) GM-CSF and TNFα cooperate in the generation of dendritic Langerhans cells. Nature 360:258–261
Chen Y-T, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914–1918
Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976–7980
Disis ML, Cheever MA (1996) Oncogenic proteins as tumor antigens. Curr Opin Immunol 8:637–642
Dranoff G, Jaffee E, Lazenbry A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543
Fenton RG, Keller CJ, Hanna N, Taub DD (1995) Induction of T-cell immunity against Ras oncoprotein by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst 87:1853–1861
Gaugler B, Van den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, DePlaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930
Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thorsby E, Gauder-nack G (1995) Vaccination with mutant Ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding Ras mutation. Lancet 346:1399–1400
Gromet MA, Epstein WL, Blois MS (1978) The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 42:2282–2292
Herr W, Wölfel T, Heike M, Meyer zum Büschenfelde K-H, Knuth A (1994) Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol Immunother 39:93–99
Jäger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A (1996 a) Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo: implications for tumor vaccines with melanoma associated antigens. Int J Cancer 66:162–169
Jäger E, Ringhoffer M, Arand M, Karbach J, Jäger D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996b) Cytolytic T cell reactivity against melanoma associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res 6:419–425
Jäger E, Ringhoffer M, Dienes H-P, Arand M, Karbach J, Jäger D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996c) Granulocyte macrophage colony-stimulating factor enhances immune responses to melanoma associated peptides in vivo. Int J Cancer 67:54–62
Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A (1996d) Inverse relationship of melanocyte differentiation antigen expression in melanoma: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470–476
Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Jäger D, Knuth A (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma mediated by antigen-specific CTL. Int J Cancer 71:142–147
Jäger E, Chen Y-T, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leucocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–269
Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Joliceur P, Greene MI (1995) Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1:644–648
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458–6462
Knuth A, Danowski B, Oettgen HF, Old LJ (1984) T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin-2-dependent T-cell cultures. Proc Natl Acad Sci USA 81:3511–3515
Knuth A, Wölfel T, Meyer zum Büschenfelde K-H (1991) Cellular and humoral responses against cancer: implications for cancer vaccines. Curr Opin Immunol 3:659–664
Knuth A, Wölfel T, Meyer zum Büschenfelde K-H (1992) T cell responses to human malignant tumors. Cancer Surv 13:39–52
Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369:67–71
Marchand M, Weymants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883–885
Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991–1045
Noguchi Y, Richards EC, Chen YT, Old LJ (1995) Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219–2223
Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA (1995) Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 154:2257–2265
Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA (1994) Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54:3124–3126
Schirmbeck R, Melber K, Reimann J (1995) Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur J Immunol 25:1063–1070
Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marthy M, Lane D, Calvo F, Soussi T (1992) Antibodies against p53 in breast cancer patients are directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380–6384
Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M (1995) Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25:1765–1769
Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, DePlaen E, Amarcostesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453–1457
Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689–698
Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647
Visseren MJW, Van Elsas A, Van der Voort EIH, Ressing ME, Kast WM, Schrier PI, Melief CJM (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991–3998
Weiner LM, Clark JI, Davey M, Li WS, Garcia-de-Palazzo I, Ring DB, Alpaugh RK (1995) Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 55:4586–4593
Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, DePlaen E, Hankeln T, Meyer zum Büschenfelde K-H, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Jäger, E., Jäger, D., Knuth, A. (1998). Strategies for the Development of Vaccines to Treat Breast Cancer. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-45769-2_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45771-5
Online ISBN: 978-3-642-45769-2
eBook Packages: Springer Book Archive